MedTrace Logo

Levosimendan Pharmacokinetics in Children

NCT01704131 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2019-08-20

No results posted yet for this study

Summary

Levosimendan is a drug used in patients with heart failure and has several advantages over other heart failure drugs. A lot of research has been done with Levosimendan in Adults, and the way the body handles the drug (pharmacokinetics) and responds to the drug (pharmacodynamics) are well established. But, in children this information is lacking despite the fact that Levosimendan is increasingly used in children of all ages. The investigators aim to describe which Levosimendan dose leads to which drug levels in children of different ages.

Conditions

  • Acute Heart Failure

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    collaborator INDUSTRY

  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • Peter P Roeleveld, MD · Leiden University Medical Center

  • Heleen E Bunker-Wiersma, MD, phd · Leiden University Medical Center

Eligibility

Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2019-09-01
Completion
2019-09-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01704131 on ClinicalTrials.gov